Cannabis Industry Council

Did you know? Cannabis-based medicines are commonly prescribed for chronic pain and anxiety. Find out more > https://lnkd.in/eRdTGHKN

Did you know? Cannabis-based medications are legally available on prescription for any condition. Find out more > https://lnkd.in/eRdTGHKN

ICYMI: End of year blog from CIC Co-Chairs Jamie Bartley & Dr Callie S. “The progress in 2024 reflects a maturing medical cannabis sector in the UK, characterised by increased prescription numbers, and the strengthening of domestic cultivation and research capabilities. “As we transition into 2025, the industrial hemp sector stands at the cusp of unprecedented opportunities. The alignment of supportive domestic policies and international frameworks underscores the growing recognition of hemp’s multifaceted benefits.” Read more > https://lnkd.in/e5xy_mCh

The International Cannabis Business Conference is once again bringing their flagship event back to Berlin in April, offering a unique combination of education, networking, and entertainment. CIC is partnering with InternationalCBC , offering a 25% discount on tickets for members. Find out more > https://lnkd.in/eDp5_nYz

New podcast: In today’s episode of the Cannabis Industry Podcast, Luke Strong speaks with Dr Callie S., Co-Chair of the Cannabis Industry Council and Research Director of AquaLabs Ltd. Listen now > https://lnkd.in/epSNUZR7

This week, our Trustees and CEO visited Downing Street to emphasize the urgent need for innovation in clinical trials and to pave a way for second-generation full-spectrum cannabinoid medicines to be licensed and made available through the NHS. Despite the 2018 change in law, current NHS pathways only accommodate first-generation isolated cannabinoid medicines. We advocate for expanding these pathways through appropriate clinical trials and creating a licensing route for second-generation full-spectrum medicines. We seek the most effective treatments for a population of children with less than a 3% chance of a new medication reducing their daily seizures once diagnosed with drug-resistant epilepsy. There is ample real-world and observational data demonstrating the positive outcomes of second-generation cannabinoid medications. With access currently limited to fewer than 50 children through the private sector, and with private options dwindling, parents are often forced to seek alternatives through the illicit market, which comes with significant risks. Our soon to be published peer-reviewed report highlights the prevalence of this practice in the UK, a situation that should be unthinkable. Supporting our call for change are Epilepsy Action, the Tuberous Sclerosis Association, CDKL5UK, the UK Infantile Spasms Trust, SRF UK, and the Medical Cannabis Clinicians Society. Their invaluable support amplifies our message, ensuring it reaches the right people. History has shown us that much greater challenges have been overcome. By working together and reaching out to those who can effect change, we have full faith that one day this will become a reality. #savetheunicorn Hannah Deacon Matt Hughes Michael Barnes Tom Cross Alice Salisbury Dr Callie S. Epilepsy Action

New blog: CIC Co-Chairs Dr Callie S. and Jamie Bartley offer their thoughts on the past year and into 2025 Read now > https://lnkd.in/e5xy_mCh

Great to see this update on CIC member Dalgety on the BBC. Congratulations! 🚀

Barcelona’s rich cannabis history and culture make it the perfect backdrop for the 2025 International Cannabis Business Conference, being held on 13 March. CIC is partnering with InternationalCBC, offering a 25% discount on tickets for members. Obtain discount > https://lnkd.in/gSGzUigz

There’s plenty to digest from yesterday’s Channel 4 Dispatches episode ‘Britain’s Benefits Scandal’ from a medical cannabis perspective. It was clear from the programme around the lack of a holistic approach to supporting claimants, with a disconnect between social security, employment, and healthcare policy. We know from extensive real-world evidence how medical cannabis can help those with conditions such as chronic pain and anxiety, some of the drivers behind long-term illness and un(der)employment. The Cannabis Industry Council recently published a health-economics study, alongside Drug Science, Ethypharm, Glass Pharms, and Rua Bioscience , looking at the impact of prescribing medical cannabis for chronic pain on the NHS. This research found that the NHS doing so would reduce the amount of time taken off work by 27 hours per patient, as well as increasing their individual earnings by hundreds of pounds. This equated to an overall potential benefit to the economy of £1.48 billion (plus a further £3.97 billion to the NHS). Read the research here > https://lnkd.in/earDEzai Watch the Dispatches episode here > https://lnkd.in/eAdSXJey